Celgene Corporation (NASDAQ:CELG) saw some unusual options trading on Thursday. Stock investors acquired 17,547 call options on the stock. This represents an increase of 214% compared to the typical volume of 5,586 call options.

In other Celgene Corporation news, Director Michael D. Casey sold 9,250 shares of the business’s stock in a transaction on Monday, June 19th. The stock was sold at an average price of $125.59, for a total value of $1,161,707.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Rupert Vessey sold 4,785 shares of the business’s stock in a transaction on Thursday, June 15th. The shares were sold at an average price of $120.18, for a total value of $575,061.30. Following the completion of the transaction, the insider now owns 4,004 shares of the company’s stock, valued at $481,200.72. The disclosure for this sale can be found here. Insiders sold a total of 253,761 shares of company stock valued at $33,792,445 over the last quarter. 0.95% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Thompson Davis & CO. Inc. lifted its holdings in shares of Celgene Corporation by 5.9% during the 2nd quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock worth $100,000 after acquiring an additional 43 shares during the period. Motco lifted its holdings in shares of Celgene Corporation by 306.9% during the 1st quarter. Motco now owns 822 shares of the biopharmaceutical company’s stock worth $102,000 after acquiring an additional 620 shares during the period. Harel Insurance Investments & Financial Services Ltd. bought a new position in shares of Celgene Corporation during the 1st quarter worth about $118,000. Penserra Capital Management LLC bought a new position in shares of Celgene Corporation during the 2nd quarter worth about $129,000. Finally, Oakworth Capital Inc. lifted its holdings in shares of Celgene Corporation by 60.9% during the 1st quarter. Oakworth Capital Inc. now owns 1,089 shares of the biopharmaceutical company’s stock worth $136,000 after acquiring an additional 412 shares during the period. Institutional investors own 79.43% of the company’s stock.

Several brokerages have weighed in on CELG. Vetr downgraded Celgene Corporation from a “strong-buy” rating to a “buy” rating and set a $146.88 price target for the company. in a report on Tuesday, August 29th. Cantor Fitzgerald reiterated a “buy” rating on shares of Celgene Corporation in a report on Monday, August 28th. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and issued a $175.00 price target on shares of Celgene Corporation in a report on Wednesday, August 9th. Cann reiterated a “buy” rating and issued a $175.00 price target on shares of Celgene Corporation in a report on Tuesday, August 1st. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $160.00 price target on shares of Celgene Corporation in a report on Monday, July 31st. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and twenty-three have given a buy rating to the company. Celgene Corporation has a consensus rating of “Buy” and an average target price of $147.38.

Celgene Corporation (CELG) opened at 139.38 on Tuesday. The firm has a market cap of $109.04 billion, a price-to-earnings ratio of 43.17 and a beta of 1.89. Celgene Corporation has a one year low of $96.93 and a one year high of $140.25. The firm has a 50-day moving average of $133.73 and a 200-day moving average of $126.08.

Celgene Corporation (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.61 by $0.21. The company had revenue of $3.27 billion for the quarter, compared to analyst estimates of $3.23 billion. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The business’s quarterly revenue was up 18.7% on a year-over-year basis. During the same period last year, the business posted $1.44 EPS. Analysts anticipate that Celgene Corporation will post $7.32 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another site, it was copied illegally and reposted in violation of United States and international trademark and copyright laws. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/09/05/celgene-corporation-target-of-unusually-high-options-trading-celg.html.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Receive News & Stock Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related stocks with our FREE daily email newsletter.